Question · asked by 1 review
Radioembolisation vs sorafenib monotherapy: All‐cause mortality at 1 year
- Population
- people with hepatocellular carcinoma
- Intervention
- Radioembolisation
- Comparison
- sorafenib monotherapy
- Outcome
- All‐cause mortality at 1 year
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Radioembolisation vs sorafenib All‐cause mortality at 1 year · people with hepatocellular carcinoma Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma (2020) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 360 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Radioembolisation vs chemoembolisation · people with hepatocellular carcinoma · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.